clinical trial · NCT07431866
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 39
HealthyRosuvastatinFurosemideMK-2828
brief summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
started
Mar 18, 2026
primary completion
Jun 7, 2026
completion
Jun 7, 2026
last updated
Mar 25, 2026
official title
A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol